Sharoon Akhtar

发表

Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells

S. Ansell, A. Chanan-Khan, S. Ansell, 2015, British journal of haematology.

Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity

Gabriela L. Borosky, A. Chanan-Khan, G. Kennedy, 2018, ChemMedChem.

Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia

M. Heckman, A. Chanan-Khan, F. Malavasi, 2019, Clinical Cancer Research.

The Novel Proteasome Inhibitor MLN2238 (Ixazomib) Induces Death In CLL Cells In Vitro and Potentiates Lethality Of Fludarabine and The BCL2 Inhibitor At-101

A. Chanan-Khan, V. Roy, J. Foran, 2013 .

The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

S. Pierrou, S. Linder, P. D'Arcy, 2016, Scientific Reports.

Targeting Bcl-2 Enhances the Anti-Tumor Effects of Lenalidomide and Dexamethasone in in Vitro and In Vivo Models of Multiple Myeloma

A. Chanan-Khan, V. Roy, A. Paulus, 2016 .

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

A. Chanan-Khan, V. Roy, B. Laplant, 2015 .

AT‐101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia

Kevin J. Thompson, Jennifer M. Carr, J. Carr, 2014, British journal of haematology.

Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications

P. Wallace, A. Chanan-Khan, K. Chitta, 2015, PloS one.

Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia

D. Mukhopadhyay, A. Chanan-Khan, R. Banerjee, 2020, Leukemia & lymphoma.

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

S. Ansell, A. Chanan-Khan, Liuyan Jiang, 2018, British journal of haematology.

Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells

A. Chanan-Khan, S. Ansell, V. Roy, 2016 .

Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

S. Pierrou, S. Linder, J. Gullbo, 2016, Scientific Reports.

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

A. Chanan-Khan, T. Witzig, S. Linder, 2015 .

Targeted Disruption of USP14 and UCHL5 with the Novel Deubiquitinase Enzyme (DUB) Inhibitor, VLX1570, Induces Immense Proteotoxicity and Cell Death in Malignant Plasma Cells

A. Chanan-Khan, R. Kyle, S. Ansell, 2014 .

Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment

Y. Asmann, A. Chanan-Khan, T. Caulfield, 2017, Blood Cancer Journal.

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

A. Chanan-Khan, V. Roy, J. Foran, 2015 .

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

A. Chanan-Khan, V. Roy, S. Ansell, 2016, Blood Cancer Journal.